Latest Monoclonal antibodies Stories
SAN JOSE, Calif., Nov.
Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo THOUSAND OAKS, Calif. and LONDON, Nov.
MONROVIA, Calif., Nov. 25, 2014 /PRNewswire/ -- Xencor, Inc.
THOUSAND OAKS, Calif., Nov.
TORONTO, Nov. 24, 2014 /PRNewswire/ - SQI Diagnostics Inc.
ReportsnReports.com adds Rheumatoid Arthritis Global Clinical Trials Review H2 2014 to its store.
-- Tanibirumab is a novel VEGFR2-neutralizing mAb for treating cancers SHENYANG, China and DAEJEON, Korea, Nov.
MAB242P, the most recently developed antibody, is the first MBS antibody to recognize both GI and GII strains of norovirus.
Sales of Biologics Will Contribute Approximately $2.3 Billion to the UC Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.
- a slit in a tire to drain away surface water and improve traction.
More Images (1 images) »